LONDON | GENEVA – As global rates of diabetes and hypertension continue to climb, nephrologists are increasingly turning to a sensitive biomarker known as Urinary Albumin (ALB) to detect kidney damage years before traditional tests fail. Medical experts are now calling for wider, routine use of the ALB test in primary care settings to curb the silent epidemic of Chronic Kidney Disease (CKD).

Urinary albumin refers to the presence of albumin protein in the urine. In a healthy kidney, the glomeruli act as a sophisticated filter, retaining essential proteins like albumin in the bloodstream. However, when this filtration barrier is damaged—often by high blood pressure or elevated blood glucose—albumin leaks into the urine. Even small amounts signal the earliest stage of kidney disease, known as microalbuminuria.

“The traditional blood test for creatinine only rises after 50% of kidney function is lost,” explains Dr. Helen Marquez, a renal specialist at the European Kidney Health Institute. “The ALB test, by contrast, acts like a smoke alarm. It detects microscopic leaks when the damage is still reversible. For patients with Type 2 diabetes or hypertension, this is a lifesaving window of opportunity.”

The ALB test is typically performed as the urine albumin-to-creatinine ratio (UACR) on a single random urine sample, making it non-invasive and cost-effective. Unlike 24-hour urine collection, the UACR corrects for urine concentration, providing accurate results instantly. Current clinical guidelines recommend that all individuals with diabetes or high blood pressure undergo UACR testing at least annually.

Recent large-scale studies have also revealed that Urinary Albumin is not just a marker of kidney disease but a powerful predictor of cardiovascular risk. Elevated levels correlate strongly with heart attacks, strokes, and heart failure, even in people without diabetes. This dual significance has prompted cardiologists to adopt the ALB test as part of routine cardiovascular assessments.

Despite its proven value, screening rates remain alarmingly low. A global survey published last month in *The Lancet Nephrology* found that fewer than 30% of at-risk patients receive annual albuminuria testing. Barriers include lack of awareness among general practitioners and the fact that early CKD causes no symptoms.

“We cannot rely on how the patient feels,” says Dr. Marquez. “Once swelling or fatigue appears, the kidney damage is often irreversible. We need to make ALB testing as routine as checking blood pressure.”

Health systems in the UK and Germany are now piloting automated alerts in electronic health records to remind doctors to order UACR tests for eligible patients. Meanwhile, new point-of-care devices capable of delivering ALB results in minutes are being deployed in community clinics.

For the millions living with silent kidney disease, a simple urine test for albumin offers the best hope of preserving function and avoiding dialysis. As public health campaigns intensify, the message is clear: check the urine, protect the kidneys.

We Baysen medicsl can supply ALB rapid test kit for early dignosis.Welcome to contact us for more details.